Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $6.6 million.

  • Crinetics Pharmaceuticals' Change in Accured Expenses rose 86613.37% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 14707.69%. This contributed to the annual value of $17.5 million for FY2024, which is 1975.01% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Change in Accured Expenses stood at $6.6 million, which was up 86613.37% from $12.5 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $12.5 million during Q2 2025, with a 5-year trough of -$1.4 million in Q1 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $3.9 million (2021), whereas its average is $3.5 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 36923.08% in 2022, then skyrocketed by 86613.37% in 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $3.9 million in 2021, then rose by 4.75% to $4.1 million in 2022, then increased by 2.65% to $4.2 million in 2023, then skyrocketed by 146.72% to $10.3 million in 2024, then tumbled by 35.72% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $12.5 million for Q2 2025, and -$1.4 million during Q1 2025.